eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
1/2024
vol. 16
 
Share:
Send email
Share:
abstract:
Original paper

Adjuvant pulse-dose-rate brachytherapy for oral cavity and oropharynx carcinoma: Outcome and toxicity assessment of 66 patients

Sophie Renard
1
,
Nicolas Demogeot
1
,
Marie Bruand
1
,
Nassim Sahki
2
,
Vincent Marchesi
1
,
William Gehin
1
,
Emilie Meknaci
1
,
Didier Peiffert
1

  1. Department of Brachytherapy, Institut de Cancérologie de Lorraine, Vandoeuvre-les-Nancy, France
  2. Methodology Biostatistics Unit, Institut de Cancérologie de Lorraine, Vandoeuvre-les-Nancy, France
J Contemp Brachytherapy 2024; 16, 1: 21–27
DOI: https://doi.org/10.5114/jcb.2024.135626
Online publish date: 2024/02/23
View full text Get citation
 
Purpose:
Brachytherapy (BT) is a validated radiation technique for treatment of early stage tumors of oral cavity and oropharynx. This study aimed to analyze the results of our institute’s patients after replacing low-dose-rate (LDR) with pulse-dose-rate (PDR) brachytherapy.

Material and methods:
We retrospectively collected data from all patients treated between 2009 and 2020 for squamous cell carcinoma (floor of the mouth, tongue, and oropharynx) using adjuvant interstitial BT with or without external RT. Primary outcome was local control. Secondary outcomes were regional control rate and toxicity. Statistical analysis of local and regional recurrences were described using Kaplan-Meier method. Prognostic value of each factor for recurrence or toxicity was evaluated with bivariate Fine-Gray model.

Results:
Data from 66 patients were analyzed. Local and regional recurrences were reported in 11% and 20% of the patients, respectively. No significant factors were identified in the present study. Grade 2 and 3 acute mucositis were reported in 21% of patients, and were more frequent in the BT only group. Almost half (47%) of the patients described acute pain following BT, and 26% required stage 2 or 3 analgesics. Trophic disorders were observed in 16 patients. Five patients presented with soft tissue necrosis (STN) and required medical treatment, of whom one subsequently required hyperbaric oxygen therapy. No predictive factors were identified for STN risk. Two patients developed osteoradionecrosis.

Conclusions:
Oral and oropharyngeal PDR-BT as adjuvant treatment is safe and effective for well-defined indications.

keywords:

brachytherapy, pulse-dose-rate, oropharynx carcinoma, oral cavity carcinoma

  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.